Seven CAR‑T products have gained regulatory approval in China, predominantly targeting CD19 (for B‑cell leukaemia and lymphoma) and BCMA (for multiple myeloma). Each product has distinct indications. At experienced centres such as Beijing Boren Hospital, clinicians select optimal CAR‑T products tailored to each patient’s disease profile, subtype and target antigen expression.